Loading company…
Ochre Bio develops genomic medicines targeting overactive genes associated with liver disease.
Founded in 2019 and based in Oxford, UK, Ochre Bio develops genomic medicines using deep phenotyping to identify liver targets and address overactive genes linked to chronic liver disease. Jack O'Meara and Quin Wills founded the company. In June 2021, it received Seed funding from Khosla Ventures, Backed VC and Appolo Health Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in